Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | DHFR | P00374 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498642 | 0.95 | DHFR (0.42) | CYP4F2CYP4A11ALDH1A1DHFRTDP1 | |
| SCHEMBL6489389 | 0.82 | L3MBTL1 (0.52) | ALDH1A1TDP1 | |
| SCHEMBL6501312 | 0.77 | L3MBTL1 (0.48) | ALDH1A1 | |
| SCHEMBL2987183 | 0.77 | CYP1A2 (0.58) | CYP4F2CYP4A11ALDH1A1DHFRTDP1 | |
| SCHEMBL10918936 | 0.76 | LTA4H (0.43) | CYP4F2CYP4A11ALDH1A1PPARGTDP1 | |
| SCHEMBL12610480 | 0.75 | CNR1 (0.47) | CYP4F2CYP4A11PPARGF2RL3 | |
| SCHEMBL8158041 | 0.75 | PPARG (0.58) | CYP4F2CYP4A11ALDH1A1PPARGTDP1 | |
| SCHEMBL13498196 | 0.74 | TDP1 (0.44) | ALDH1A1HDAC1TDP1 | |
| SCHEMBL7371527 | 0.74 | TBXAS1 (0.47) | CYP4F2CYP4A11PPARGDHFRLTA4H | |
| SCHEMBL30734588 | 0.74 | CYP4F2 (0.45) | CYP4F2CYP4A11ALDH1A1PPARGTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | CYP4F2 279/4885CYP4A11 268/4885ALDH1A1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.